Bristol-Myers Squibb Company (BMY) Q4 2025 (USD): Adj. EPS 1.26 (exp. 1.23), Revenue 12.5bln (exp. 12.28bln)
Importance
Level 1
- Adj. EPS includes net impact of -0.60 due to acquired IPR&D charges and licensing income.
Guidance:
- 2026 revenue 46-47.5bln (exp. 44.16bln).
- 2026 adj. EPS 6.05-6.35 (exp. 6.02).
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#BRISTOL-MYERS SQUIBB CO#BMY.US#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#DXY#US EQUITIES